CED

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

Retrieved on: 
Wednesday, April 24, 2024
First wave, CED, Research, Coeliac disease, ULN, Serology, Patient, Diet, BOCA, Manuscript, Pharmaceutical industry

Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).

Key Points: 
  • Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
  • The featured paper is entitled “Dynamics of Serologic Change to Gluten in Celiac Disease Patients” (doi.org/10.3390/nu15245083).
  • “Our focus on developing latiglutenase is bolstered by this groundbreaking CeD research, just one component of the scientific, clinical, and regulatory expertise in gastroenterological drug development that Jack Syage and his team, formerly from ImmunogenX, bring to First Wave,” stated James Sapirstein, Chairman and CEO of First Wave.
  • “The evidence produced from this rich deposit of clinical data advances not only the development of latiglutenase but also benefits the whole field of celiac disease research in order to bring needed relief to the millions who suffer from this disease.”

CED Announces Recipients of Its 2024 Distinguished Leadership Awards

Retrieved on: 
Thursday, April 18, 2024
Corporation, The Conference Board, Conference, Public policy, Byron Boston, Committee, CED, Economic development

NEW YORK, April 18, 2024 /PRNewswire/ -- Today, the Committee for Economic Development, the public policy center of The Conference Board (CED), announced the outstanding business leaders and their companies that will be receiving the 2024 CED Distinguished Leadership Awards.

Key Points: 
  • NEW YORK, April 18, 2024 /PRNewswire/ -- Today, the Committee for Economic Development, the public policy center of The Conference Board (CED), announced the outstanding business leaders and their companies that will be receiving the 2024 CED Distinguished Leadership Awards.
  • The 2024 Awards Celebration will be held on October 9, 2024, in New York City, where the honorees will be introduced by leading executives—all of whom are distinguished leaders in their own right.
  • This year's CED Awards Committee is co-chaired by Peter Altabef, Chair and CEO of Unisys; Byron Boston, Chairman and CEO of Dynex Capital, Inc.; and Dr. Lori Esposito Murray, CED Trustee and former President of CED.
  • CED is pleased to announce the recipients of the 2024 Distinguished Leadership Awards for Business Stewardship and Corporate Citizenship:

aiOla's Speech AI Technology Outperforms OpenAI's Whisper in Recognizing Jargon

Retrieved on: 
Thursday, April 18, 2024
Speech, OpenAI, Automation, CED, Whispering, Communication, TEL, Safety

TEL AVIV, Israel, April 18, 2024 /PRNewswire/ -- aiOla, an AI-powered technology that automates business workflows by capturing spoken data, has announced a major milestone in speech recognition. aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon. The patented AdaKWS model achieved 95% accuracy in keyword spotting, surpassing OpenAI's industry-leading Whisper model which reached 88% accuracy.

Key Points: 
  • aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon.
  • Keyword spotting is an essential aspect of speech recognition that tackles the problem of identifying jargon by detecting predefined words and phrases.
  • aiOla's process automation applications can accurately understand speech, jargon and acronyms across over 100 languages, regardless of accents and background noises.
  • This enables aiOla's solution to be instantly adapted to the jargon of any industry without needing to retrain its AI model.

aiOla's Speech AI Technology Outperforms OpenAI's Whisper in Recognizing Jargon

Retrieved on: 
Thursday, April 18, 2024
Speech, OpenAI, Automation, CED, Whispering, Communication, TEL, Safety

TEL AVIV, Israel, April 18, 2024 /PRNewswire/ -- aiOla, an AI-powered technology that automates business workflows by capturing spoken data, has announced a major milestone in speech recognition. aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon. The patented AdaKWS model achieved 95% accuracy in keyword spotting, surpassing OpenAI's industry-leading Whisper model which reached 88% accuracy.

Key Points: 
  • aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon.
  • Keyword spotting is an essential aspect of speech recognition that tackles the problem of identifying jargon by detecting predefined words and phrases.
  • aiOla's process automation applications can accurately understand speech, jargon and acronyms across over 100 languages, regardless of accents and background noises.
  • This enables aiOla's solution to be instantly adapted to the jargon of any industry without needing to retrain its AI model.

As AI Transforms the Economy, CED Provides Plan to Future-Proof Workforce

Retrieved on: 
Tuesday, April 16, 2024
Education, Public policy, Workforce, System, Learning, NIH, Policy, AI, The Conference Board, Conference, Federal, Research, STEM, NSF, Committee, Private sector, CED, Student, Capitalism, Economic development, Knowledge, Management

It offers solutions for business and policy leaders to respond proactively to the AI transformation by equipping workers with the knowledge and tools to adapt and thrive.

Key Points: 
  • It offers solutions for business and policy leaders to respond proactively to the AI transformation by equipping workers with the knowledge and tools to adapt and thrive.
  • "AI's impact on workers and the economy is simply too large—and consequential—to be ignored," said John Gardner, Vice President, Public Policy at CED.
  • Expand Federal AI research initiatives in academic institutions through NSF, NIH, and other agencies, including research on human-complementary technology.
  • Build AI expertise to drive government's response to AI challenges and to review and advise on how government workers use AI technology.

CED Testifies Before Congress on Child Care's Economic Impact

Retrieved on: 
Thursday, April 11, 2024
Congress, Small business, Hearing, Child care, The Conference Board, Conference, Parent, Research, Public policy, Environment, Committee, Workforce, CED, Student, Role, Economic development, Entrepreneurship, Management

NEW YORK, April 11, 2024 /PRNewswire/ -- The Committee for Economic Development (CED), the public policy center of The Conference Board, testified before Congress earlier this week.

Key Points: 
  • NEW YORK, April 11, 2024 /PRNewswire/ -- The Committee for Economic Development (CED), the public policy center of The Conference Board, testified before Congress earlier this week.
  • The testimony was given by Cindy Cisneros, Vice President of Education Programs at CED, who spoke about CED's findings and recommendations from its report, Child Care in State Economies , addressing issues related to the accessibility and affordability of quality child care.
  • The economic model for child care makes it difficult for home-based providers to stay in the business and for child care centers to hire and retain high-quality staff, which also impacts choices for parents.
  • While there is no easy way to make quality child care more available and affordable, there are a variety of approaches to address child care supply and cost.

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
Monday, March 18, 2024
Inflammation, Health, Conference, Database, Patient, Serology, Research, Lymphocyte, Gastrointestinal disease, Doctor of Philosophy, CED, First wave, Abstract, Gastroenterology, DDW, Coeliac disease, IEL

BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024, in Washington, D.C.

Key Points: 
  • “The abstracts accepted for presentation at DDW 2024 showcase significant advancements in the field of gastroenterology, particularly in the precision diagnosis and management of celiac disease through the innovative VCIEL scale that our team has developed,” stated James Sapirstein, Chairman and CEO of First Wave BioPharma.
  • Details on the presentations are as follows:
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma

CED Provides Plan to Restore Confidence in America's Elections

Retrieved on: 
Tuesday, March 19, 2024
Credible, CISA, Democracy, Congress, Conference, The Conference Board, Business, Committee, Public policy, Election, Social media, News, Software, Ageing, Commit, Outline, Dropbox, Crowding, Capitalism, Safety, Government, Economic development, CED, Human

The Solutions Brief—the latest in CED's Sustaining Capitalism series—comes as confidence in America's elections is still recovering from the lows of 2020.

Key Points: 
  • The Solutions Brief—the latest in CED's Sustaining Capitalism series—comes as confidence in America's elections is still recovering from the lows of 2020.
  • "Both policymakers and private sector leaders must act now to ensure that the 2024 election is secure, credible, and accessible."
  • Secure our elections and rebuild trust in the elections process.
  • Reality resource, which addresses common disinformation narratives by providing accurate information related to elections, to build trust in voting infrastructure.

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Retrieved on: 
Friday, February 23, 2024
Type 1, DMG, NCT, CED, Neuro-Oncology (journal), Pons, Safety, Convection, Patient, Survival, Columbia University, Pharmaceutical industry

Nine patients were treated in the study (30 M group, n=3; 60 M group, n=4; 90 M group (optimal dose), n=2).

Key Points: 
  • Nine patients were treated in the study (30 M group, n=3; 60 M group, n=4; 90 M group (optimal dose), n=2).
  • Although the study was not powered to reliably demonstrate efficacy, median overall survival (OS) of patients in the study was 16.5 months.
  • This compares favourably with median survival rate in a cohort of 316 cases of 10.0 months (Jansen et al, 2015.
  • The results of the experiment were inconclusive in that they did not correlate with the results previously seen in in vitro and in vivo studies of tolimidone.

Parspec Announces $11.5M Seed Funding led by Innovation Endeavors, bringing the power of AI to construction product procurement

Retrieved on: 
Tuesday, February 27, 2024
Other Construction & Property, Technology, Construction & Property, Artificial Intelligence, Software, Katerra, Eric Schmidt, CED, AI, Building, Sale, Database, Documentation, LLM, Lighting, Stanford University, Operation, NLP

Parspec , an AI-powered software platform that streamlines the selection and sale of construction products, today announced its oversubscribed $11.5 million seed round.

Key Points: 
  • Parspec , an AI-powered software platform that streamlines the selection and sale of construction products, today announced its oversubscribed $11.5 million seed round.
  • Innovation Endeavors led the investment, with participation from Building Ventures, Heartland Ventures, and Hometeam Ventures.
  • Founded in 2021, Parspec is transforming the $1.7 trillion global construction materials market by providing better information and online workflows to support the procurement process.
  • It is a time consuming and error-prone process that contributes to procurement costs (in construction) that are nearly double comparable industries.